Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques

Biochemical and Biophysical Research Communications

Volumn 371, Issue 4, 2008, Pages 850-854

  Moriya, Chikaya ^a   Horiba, Satoshi ^a   Inoue, Makoto ^b   Iida, Akihiro ^b   Hara, Hiroto ^b   Shu, Tsugumine ^b   Hasegawa, Mamoru ^b   Matano, Tetsuro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b University of Tokyo   (Japan)

Author keywords

AIDS vaccine; CTL; Neutralizing antibody; Sendai virus vector; SIV

Indexed keywords

ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ANTIBODY TITER; ARTICLE; FEASIBILITY STUDY; HOST; MACACA; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SENDAI VIRUS; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS; GENETIC VECTORS; LYMPHOCYTE ACTIVATION; MACACA MULATTA; NEUTRALIZATION TESTS; SENDAI VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

MACACA; MACACA MULATTA; SENDAI VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 44149113490     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.156     Document Type: Article

References (21)

1. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., and Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68 (1994) 4650-4655
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68 (1994) 6103-6110
3. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., and Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72 (1998) 164-169
4. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., Irwin C.E., Safrit J.T., Mittler J., Weinberger L., Kostrikis L.G., Zhang L., Perelson A.S., and Ho D.D. Dramatic rise in plasma viremia after CD8(+) T-cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189 (1999) 991-998
5. + lymphocytes. Science 283 (1999) 857-860
6. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat. Med. 9 (2003) 874-880
7. Sumida S.M., Truitt D.M., Lemckert A.A.C., Vogels R., Custers J.H.H.V., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., Lifton M.A., Essex M., Walker B.D., Goudsmit J., Havenga M.J.E., and Barouch D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174 (2005) 7179-7185
8. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Gu L., Martin J.E., Novik L., Chakrabarti B.K., Butman B.T., Gall J.G., King C.R., Andrews C.A., Sheets R., Gomez P.L., Mascola J.R., Nabel G.J., and Graham B.S. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194 (2006) 1638-1649
9. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., Santiago S., Marmor M., Lally M., Novak R.M., Brown S.J., Kulkarni P., Dubey S.A., Kierstead L.S., Casimiro D.R., Mogg R., Dinubile M.J., Shiver J.W., Leavitt R.Y., Robertson M.N., Mehrotra D.V., and Quirk E. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis (2008) Epub ahead of print
10. Matano T., Kano M., Nakamura H., Takeda A., and Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J. Virol. 75 (2001) 11891-11896
11. Kano M., Matano T., Kato A., Nakamura H., Takeda A., Suzaki Y., Ami Y., Terao K., and Nagai Y. Primary replication of a recombinant Sendai virus vector in macaques. J. Gen. Virol. 83 (2002) 1377-1386
12. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., Sugimoto C., Mori K., Iida A., Hirata T., Hasegawa M., Yuasa T., Miyazawa M., Takahashi Y., Yasunami M., Kimura A., O'Connor D.H., Watkins D.I., and Nagai Y. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199 (2004) 1709-1718
13. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev. Med. Virol. 9 (1999) 83-99
14. Skiadopoulos M.H., Surman S.R., Riggs J.M., Elkins W.R., St Claire M., Nishio M., Garcin D., Kolakofsky D., Collins P.L., and Murphy B.R. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 297 (2002) 153-160
15. Kato M., Igarashi H., Takeda A., Sasaki Y., Nakamura H., Kano M., Sata T., Iida A., Hasegawa M., Horie S., Higashihara E., Nagai Y., and Matano T. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine 23 (2005) 3166-3173
16. Matano T., Kano M., Odawara T., Nakamura H., Takeda A., Mori K., Sato T., and Nagai Y. Induction of protective immunity against pathogenic simian immunodeficiency virus by a foreign receptor-dependent replication of an engineered avirulent virus. Vaccine 18 (2000) 3310-3318
17. Kato A., Kiyotani K., Sakai Y., Yoshida T., and Nagai Y. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J. 16 (1997) 578-587
18. Matano T., Kano M., Takeda A., Nakamura H., Nomura N., Furuta Y., Shioda T., and Nagai Y. No significant enhancement of protection by Tat-expressing Sendai viral vector-booster in a macaque AIDS model. AIDS 17 (2003) 1392-1394
19. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., Ueda Y., Lee Y.S., Fukumura M., Iida A., Kato A., Nagai Y., and Hasegawa M. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74 (2000) 6564-6569
20. Yoshizaki M., Hironaka T., Iwasaki H., Ban H., Tokusumi Y., Iida A., Nagai Y., Hasegawa M., and Inoue M. Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. J. Gene. Med. 8 (2006) 1151-1159
21. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., Portner A., Coleclough C., and Hurwitz J.L. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22 (2004) 3182-3186